GlassScriptPhysician profile
Vijay Jayaraman
NPI 1811195092
$27,774.96
in general payments reported to CMS, 2019-2025
41 companies · $2,611 in 2025
The $2,611 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,263 · 2020: $3,348 · 2021: $3,962 · 2022: $7,653 · 2023: $4,035 · 2024: $1,904 · 2025: $2,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,192 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,250 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,191.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,250.00 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,021.91 | 2019-2025 | |
| Boston Scientific Corporation | $2,847.53 | 2019-2025 | Spaceoar Vue System - 10ml, Overstitch Endoscopic Suturing System, Exalt Model D |
| Endogastric Solutions, INC | $577.05 | 2019-2024 | Esophyx |
| Janssen Biotech, INC. | $565.83 | 2019-2025 | Stelara, Tremfya, Simponi |
| Olympus America INC. | $479.78 | 2019-2025 | Visiglide |
| Takeda Pharmaceuticals U.S.A., INC. | $476.17 | 2019-2025 | Entyvio, Gattex |
| Cook Medical LLC | $457.43 | 2019-2025 | Hemospray, Echotip Insight |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.30 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Ambu INC. | $389.83 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $351.57 | 2024-2025 | Zenpep |
| Alcresta Therapeutics, INC. | $319.80 | 2019-2022 | |
| Covidien LP | $303.94 | 2019 | |
| Qol Medical, LLC | $279.73 | 2019-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $210.40 | 2019-2024 | |
| Erbe USA INC | $193.00 | 2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $191.56 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $177.26 | 2019-2025 | |
| Redhill Biopharma INC. | $166.65 | 2020-2022 | |
| Fujifilm Healthcare Americas Corporation | $149.27 | 2019 | |
| Conmed Corporation | $143.65 | 2021-2025 | Conmed Eus |
| Celgene Corporation | $140.89 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $121.48 | 2023-2025 | Dupixent |
| Genzyme Corporation | $108.82 | 2023-2024 | |
| Braintree Laboratories, INC. | $102.89 | 2019-2023 | Suflave, Sutab |
| Intra-Sana Laboratories | $83.68 | 2021-2023 | Reltone 400 Mg, Reltone 200 Mg |
| Ardelyx, INC. | $78.31 | 2022-2023 | Ibsrela |
| Ethicon US, LLC | $57.43 | 2019-2021 | |
| Daiichi Sankyo INC. | $46.80 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $45.90 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $36.90 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $29.72 | 2023 | |
| Madrigal Pharmaceuticals | $26.29 | 2025 | Rezdiffra |
| Pfizer INC. | $24.79 | 2025 | |
| Ucb, INC. | $24.29 | 2019 | |
| Orphalan INC | $23.43 | 2024 | Cuvrior |
| Celltrion USA INC. | $19.44 | 2025 | Vegzelma |
| Sandoz INC. | $17.85 | 2025 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $16.62 | 2021 | |
| Alfasigma USA, INC. | $14.91 | 2020 | |
| Shionogi INC | $13.10 | 2020 | |
| Medtronic, INC. | $12.76 | 2023 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Jayaraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.